A neoadjuvant trial approach for PD-L1 blockade in chordoma would be interesting to determine whether targeting the chordoma PD-L1+ CSC subpopulation prior to standard of care surgical resection would help reduce disease recurrence. This evidence concerns the gene CD274 and chordoma.